Mid-Southern Bancorp (NASDAQ:MSVB) reported quarterly earnings of $0.13 per share. This is a 30 percent increase over earnings of $0.10 per share from the same period last year.
FDA Accepted Submission of Supplemental New Drug Application for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S.
